ado-trastuzumab emtansine + bintrafusp alfa + entinostat

This is an investigational combination therapy consisting of three agents with distinct mechanisms of action, primarily under evaluation for cancer treatment: **Ado-trastuzumab emtansine** is an antibody-drug conjugate composed of the monoclonal antibody trastuzumab linked to the cytotoxic agent DM1. It targets HER2-positive cancer cells, delivering DM1 directly to these cells and inhibiting their proliferation. **Bintrafusp alfa** is a bifunctional fusion protein that simultaneously blocks programmed death-ligand 1 (PD-L1) and traps transforming growth factor-beta (TGF-beta), aiming to enhance anti-tumor immune responses by overcoming two major immunosuppressive pathways in the tumor microenvironment. **Entinostat** is a selective oral small-molecule inhibitor of class I histone deacetylases. By inhibiting HDACs, it induces hyperacetylation of histones, leading to transcriptional activation of genes involved in cell cycle arrest, differentiation, apoptosis, and modulation of immune responses[2][3][5]. The combination aims to synergistically target tumor cells through direct cytotoxicity, immune checkpoint inhibition/immune modulation, and epigenetic reprogramming.

Other names

T-DM1T-DM-1T-DM 1M7824M-7824M 7824SNDX 275SNDX275SNDX-275MS 275MS275MS-275